MedTrace Logo

Ultra-low-dose Whole-body CT Using AI-based CT Reconstruction in Patients With Multiple Myeloma

NCT05577884 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 30

Last updated 2022-11-08

No results posted yet for this study

Summary

This prospective study aims to perform intra-individual comparison of the image quality between ultra-low-dose whole-body CT with deep learning reconstruction and conventional low-dose whole-body CT with iterative reconstruction in patients with suspected multiple myeloma.

Conditions

Interventions

DIAGNOSTIC_TEST

noncontrast-enhanced whole-body CT

noncontrast-enhanced low-dose whole-body CT using dual-source CT scanner using A-tube (75% radiation) and B-tube (25% radiation). * conventional low-dose CT data (A +B tubes, 100% dose) are reconstructed with iterative reconstruction * ultra-low dose CT data (B-tube only, 25% dose) are reconstructed with deep learning commercially available software.

Sponsors & Collaborators

  • Seoul National University Hospital

    lead OTHER

Principal Investigators

  • Hee-Dong Chae, MD · Seoul National University Hospital

Eligibility

Min Age
19 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-10-06
Primary Completion
2022-12-31
Completion
2023-02-28
FDA Device
Yes

Countries

  • South Korea

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05577884 on ClinicalTrials.gov